+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pen and Injector Drug Delivery Devices Market Size, Share & Trends Analysis Report by Product, Therapeutic Use, End-use, Region, and Segment Forecasts, 2026-2033

  • PDF Icon

    Report

  • 120 Pages
  • January 2026
  • Region: Global
  • Grand View Research
  • ID: 6227998
The global pen and injector drug delivery devices market size was estimated at USD 114.67 billion in 2025 and is projected to reach USD 236.54 billion by 2033, growing at a CAGR of 9.6% from 2026 to 2033. This strong growth is driven by the rising demand for advanced, effective, and user-friendly drug delivery solutions across healthcare settings..

Key drivers include the increasing prevalence of chronic conditions such as diabetes, cancer, and autoimmune disorders that require frequent injections; growing adoption of user-friendly injection tools such as autoinjectors and pen injectors; and continuous technological advancements that enhance safety, accuracy, and patient comfort. In addition, growing biological development, the shift toward home-based care, and greater focus on reducing hospital visits are further supporting market growth.

One of the major drivers of the pen and injector drug delivery devices market is the increasing prevalence of chronic diseases, along with the rapid growth of the geriatric population. Chronic conditions such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders often require regular or long-term medication delivered through injections for fast and effective therapeutic action. According to the IDF’s 2021 report, about 537 million people around the world had diabetes, which means roughly 1 in 10 people were affected. The number is expected to rise sharply, reaching 783 million people by 2045. As these diseases become more common in the world, the demand for reliable and easy-to-use injectable devices continues to increase. In addition, the aging population faces multiple health issues and typically requires frequent medical treatments, including injectable drugs. According to the recent population estimates and projections by UN DESA’s Population Division, the number of people aged 60 and older is projected to reach 1.5 billion by 2050, representing about 1 in 6 people globally. This demographic shift is supporting the need for convenient, safe, and precise delivery systems that support both clinical use and home-based care, thereby contributing significantly to market growth.

Technological advancements in drug delivery systems are driving the growth of pen and injector drug delivery devices. Innovations have made injection devices safer, more efficient, and easier for patients to use. Features such as smart autoinjectors with digital monitoring, needle-free injection technologies, and improved safety mechanisms help ensure accurate dosing and reduce the risk of needle injuries. Advancements in materials and device design also enhance comfort and support self-use at home, which is becoming increasingly important for people managing chronic diseases. For instance, in October 2024, BD and Ypsomed announced a strategic collaboration to integrate BD’s Neopak XtraFlow glass prefillable syringe, featuring a shorter 8 mm needle and a thinner-wall cannula, with Ypsomed’s YpsoMate 2.25 autoinjector. This design makes high-viscosity biologic drugs easier to inject for patients self-administering at home, and the two-step injector is purpose-built to assist users with
limited grip or vision. Such technological improvements encourage adoption and support significant market growth.

Global Pen And Injector Drug Delivery Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global pen and injector drug delivery devices market report on the basis of product, therapeutic use, end use, and region.
  • Product Outlook (Volume, Units; Revenue, USD Billion, 2021-2033)
  • Injectors
  • Pen
  • Therapeutic Use Outlook (Volume, Units; Revenue, USD Billion, 2021-2033)
  • Autoimmune Disorders
  • Hormonal Disorders
  • Oncology
  • Obesity
  • Diabetes Mellitus
  • Others
  • End Use Outlook (Volume, Units; Revenue, USD Billion, 2021-2033)
  • Hospitals
  • Homecare Settings
  • Others
  • Regional Outlook (Volume, Units; Revenue, USD Billion, 2021-2033)
  • North America
  • Europe
  • Asia

Why You Should Buy This Report

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Product
1.2.2. Drug Type
1.2.3. Therapeutic Use
1.2.4. End Use
1.3. Estimation and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Materials & Third-Party Perspectives
1.5.4. Primary Research
1.6. Information or Data Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Validation
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.8.1.1. Research Scope and Assumptions
1.8.1.2. Research Methodology and Assumptions
1.8.2. Volume Price Analysis
1.8.3. CDMO Pen and Injector Drug Delivery Devices Market
1.9. List of Secondary Sources
1.10. List of Abbreviations
1.11. Objectives
1.11.1. Objective 1
1.11.2. Objective 2
1.11.3. Objective 3
Chapter 2. Executive Summary
2.1. Market Snapshot (Regional)
2.2. Segment Snapshot (Product)
2.3. Segment Snapshot (Therapeutic Use)
2.4. Segment Snapshot (End Use)
2.5. Market Concentration
Chapter 3. Pen and Injector Drug Delivery Devices Market Variables and Trends Market Lineage Outlook
3.1. Market Dynamics
3.1.1. Market Driver Impact Analysis
3.1.2. Market Restraint Analysis
3.1.3. Market Opportunity Analysis
3.2. Industry Analysis Tools
3.2.1. Porter’s Five Forces Analysis
3.2.2. Macroeconomic Analysis
3.3. List of CDMO Manufacturers and Supplied Pen and Injector Drug Delivery Devices to Companies
3.4. List of In-House Manufacturers of Pen and Injector Drug Delivery Devices
3.5. Qualitative Insights on Potential Impact of New Injectables or Oral Drugs and Development of Multi-Dose Devices, by Region
3.5.1. North America
3.5.2. Europe
3.5.3. Asia
3.6. Global CDMO Pen and Injector Drug Delivery Devices Market, by Product, 2021-2033 (value in USD Billion and Volume in Units Sold)
3.6.1. Global CDMO Pen and Injector Drug Delivery Devices Market, by Product, 2021-2033 (USD Billion)
3.6.2. Global CDMO Pen and Injector Drug Delivery Devices Market, by Product, 2021-2033 (Units)
Chapter 4. Pen and Injector Drug Delivery Devices Market: Product Analysis
4.1. Product Movement Analysis & Market Share, 2025 & 2033
4.2. Pen and Injector Drug Delivery Devices Market Estimates & Forecast, by Product (USD Billion, Units)
4.3. Market Size & Forecasts and Trend Analysis, 2021 to 2033
4.3.1. Injectors
4.3.1.1. Injectors Market, 2021-2033 (USD Billion, Units)
4.3.1.2. GLP-1 Agonists
4.3.1.2.1. GLP-1 Agonists Market, 2021 to 2033 (USD Billion, Units)
4.3.1.3. Hormone Therapies
4.3.1.3.1. Hormone Therapies Market, 2021 to 2033 (USD Billion, Units)
4.3.1.4. Biologics
4.3.1.4.1. Biologics Market, 2021 to 2033 (USD Billion, Units)
4.3.1.5. Others
4.3.1.5.1. Others Market, 2021 to 2033 (USD Billion, Units)
4.3.2. Pen
4.3.2.1. Pens Market, 2021-2033 (USD Billion, Units)
4.3.2.2. GLP-1 Agonists
4.3.2.2.1. GLP-1 Agonists Market, 2021 to 2033 (USD Billion, Units)
4.3.2.3. Insulin
4.3.2.3.1. Insulin Market, 2021 to 2033 (USD Billion, Units)
4.3.2.4. Hormone Therapies
4.3.2.4.1. Hormone Therapies Market, 2021 to 2033 (USD Billion, Units)
4.3.2.5. Others
4.3.2.5.1. Other Market Estimates & Forecasts, 2021 to 2033 (USD Billion, Units)
Chapter 5. Pen and Injector Drug Delivery Devices Market: Therapeutic Use Estimates & Trend Analysis
5.1. Therapeutic Area Movement Analysis & Market Share, 2025 & 2033
5.2. Pen and Injector Drug Delivery Devices Market Estimates & Forecast, by Therapeutic Use (USD Billion, Units)
5.3. Market Size & Forecasts and Trend Analysis, 2021 to 2033
5.3.1. Autoimmune Disorders
5.3.1.1. Autoimmune Disorders Market, 2021 to 2033 (USD Billion, Units)
5.3.2. Hormonal Disorders
5.3.2.1. Hormonal Disorders Market, 2021 to 2033 (USD Billion, Units)
5.3.3. Oncology
5.3.3.1. Oncology Market, 2021 to 2033 (USD Billion, Units)
5.3.4. Obesity
5.3.4.1. Obesity Market, 2021 to 2033 (USD Billion, Units)
5.3.5. Diabetes Mellitus
5.3.5.1. Diabetes Mellitus Market, 2021 to 2033 (USD Billion, Units)
5.3.6. Others
5.3.6.1. Others Market, 2021 to 2033 (USD Billion, Units)
Chapter 6. Pen and Injector Drug Delivery Devices Market: End Use Analysis
6.1. End Use Movement Analysis & Market Share, 2025 & 2033
6.2. Pen and Injector Drug Delivery Devices Market Estimates & Forecast, by End Use (USD Billion, Units)
6.3. Market Size & Forecasts and Trend Analysis, 2021 to 2033
6.3.1. Hospitals
6.3.1.1. Hospitals Market, 2021 to 2033 (USD Billion, Units)
6.3.2. Homecare Settings
6.3.2.1. Homecare Settings Market, 2021 to 2033 (USD Billion, Units)
6.3.3. Others
6.3.3.1. Others Market, 2021 to 2033 (USD Billion, Units)
Chapter 7. Pen and Injector Drug Delivery Devices Market: Regional Estimates & Trend Analysis
7.1. Pen and Injector Drug Delivery Devices Market: Regional Outlook
7.2. North America
7.2.1. North America Pen and Injector Drug Delivery Devices Market estimates and forecasts, 2021-2033 (USD Billion, Units)
7.2.2. U.S.
7.2.2.1. Competitive Scenario
7.2.2.2. Regulatory framework
7.2.2.3. Reimbursement Structure
7.2.2.4. U.S. Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.2.3. Canada
7.2.3.1. Competitive Scenario
7.2.3.2. Regulatory framework
7.2.3.3. Reimbursement Structure
7.2.3.4. Canada Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.2.4. Mexico
7.2.4.1. Competitive Scenario
7.2.4.2. Regulatory framework
7.2.4.3. Reimbursement Structure
7.2.4.4. Mexico Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.3. Europe
7.3.1. Europe Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.3.2. UK
7.3.2.1. Competitive Scenario
7.3.2.2. Regulatory framework
7.3.2.3. Reimbursement Structure
7.3.2.4. UK Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.3.3. Germany
7.3.3.1. Competitive Scenario
7.3.3.2. Regulatory framework
7.3.3.3. Reimbursement Structure
7.3.3.4. Germany Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.3.4. France
7.3.4.1. Competitive Scenario
7.3.4.2. Regulatory framework
7.3.4.3. Reimbursement Structure
7.3.4.4. France Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.3.5. Italy
7.3.5.1. Competitive Scenario
7.3.5.2. Regulatory framework
7.3.5.3. Reimbursement Structure
7.3.5.4. Italy Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.3.6. Spain
7.3.6.1. Competitive Scenario
7.3.6.2. Regulatory framework
7.3.6.3. Reimbursement Structure
7.3.6.4. Spain Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.3.7. Norway
7.3.7.1. Competitive Scenario
7.3.7.2. Regulatory framework
7.3.7.3. Reimbursement Structure
7.3.7.4. Norway Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.3.8. Sweden
7.3.8.1. Competitive Scenario
7.3.8.2. Regulatory framework
7.3.8.3. Reimbursement Structure
7.3.8.4. Sweden Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.3.9. Denmark
7.3.9.1. Competitive Scenario
7.3.9.2. Regulatory framework
7.3.9.3. Reimbursement Structure
7.3.9.4. Denmark Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.4. Asia
7.4.1. Asia Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.4.2. China
7.4.2.1. Competitive Scenario
7.4.2.2. Regulatory framework
7.4.2.3. Reimbursement Structure
7.4.2.4. China Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.4.3. Japan
7.4.3.1. Competitive Scenario
7.4.3.2. Regulatory framework
7.4.3.3. Reimbursement Structure
7.4.3.4. Japan Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.4.4. India
7.4.4.1. Competitive Scenario
7.4.4.2. Regulatory framework
7.4.4.3. Reimbursement Structure
7.4.4.4. India Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.4.5. Thailand
7.4.5.1. Competitive Scenario
7.4.5.2. Regulatory framework
7.4.5.3. Reimbursement Structure
7.4.5.4. Thailand Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.4.6. South Korea
7.4.6.1. Competitive Scenario
7.4.6.2. Regulatory framework
7.4.6.3. Reimbursement Structure
7.4.6.4. South Korea Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.4.7. Saudi Arabia
7.4.7.1. Competitive Scenario
7.4.7.2. Regulatory framework
7.4.7.3. Reimbursement Structure
7.4.7.4. Saudi Arabia Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.4.8. UAE
7.4.8.1. Competitive Scenario
7.4.8.2. Regulatory framework
7.4.8.3. Reimbursement Structure
7.4.8.4. UAE Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
7.4.9. Kuwait
7.4.9.1. Competitive Scenario
7.4.9.2. Regulatory framework
7.4.9.3. Reimbursement Structure
7.4.9.4. Kuwait Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021-2033 (USD Billion, Units)
Chapter 8. Pen and Injector Drug Delivery Devices Market: Competitive Analysis
8.1. Company Categorization
8.2. Participant’s Overview
8.3. Financial Performance
8.4. Product Offerings
8.5. Company Market Position Analysis
8.6. Company Market Share Analysis, 2024 (%)
8.7. Strategy Mapping
8.7.1. Product Launches & Approvals
8.7.2. Partnerships & Collaborations
8.7.3. Mergers & Acquisitions
8.7.4. Expansions
8.7.5. Others
8.8. Company Profiles
8.8.1. Novo Nordisk A/S
8.8.1.1. Company Overview
8.8.1.2. Financial Performance
8.8.1.3. Product Benchmarking
8.8.1.4. Strategic Initiatives
8.8.2. Sanofi
8.8.2.1. Company Overview
8.8.2.2. Financial Performance
8.8.2.3. Product Benchmarking
8.8.2.4. Strategic Initiatives
8.8.3. Eli Lilly and Company
8.8.3.1. Company Overview
8.8.3.2. Financial Performance
8.8.3.3. Product Benchmarking
8.8.3.4. Strategic Initiatives
8.8.4. AstraZeneca plc
8.8.4.1. Company Overview
8.8.4.2. Financial Performance
8.8.4.3. Product Benchmarking
8.8.4.4. Strategic Initiatives
8.8.5. Pfizer, Inc.
8.8.5.1. Company Overview
8.8.5.2. Financial Performance
8.8.5.3. Product Benchmarking
8.8.5.4. Strategic Initiatives
8.8.6. Merck KGaA
8.8.6.1. Company Overview
8.8.6.2. Financial Performance
8.8.6.3. Product Benchmarking
8.8.6.4. Strategic Initiatives
8.8.7. Teva Pharmaceuticals
8.8.7.1. Company Overview
8.8.7.2. Financial Performance
8.8.7.3. Product Benchmarking
8.8.7.4. Strategic Initiatives
8.8.8. Amgen, Inc.
8.8.8.1. Company Overview
8.8.8.2. Financial Performance
8.8.8.3. Product Benchmarking
8.8.8.4. Strategic Initiatives
8.8.9. Ferring Pharmaceuticals
8.8.9.1. Company Overview
8.8.9.2. Financial Performance
8.8.9.3. Product Benchmarking
8.8.9.4. Strategic Initiatives
8.8.10. AbbVie, Inc.
8.8.10.1. Company Overview
8.8.10.2. Financial Performance
8.8.10.3. Product Benchmarking
8.8.10.4. Strategic Initiatives
List of Tables
Table 1. List of abbreviations
Table 2. Estimated number of new cancer cases for all cancer types from 2025 to 2030, Incidence, Both sexes, age [0-85+]
Table 3. Estimated global prevalence and mortality of major chronic diseases, 2025
Table 4. Comparison of pen and injector drug delivery devices and conventional therapies: cost and long-term value
Table 5. Device preferences for top biologic classes
Table 6. Regional comparison of injectable drug delivery ecosystem maturity in North America
Table 7. Europe diabetes burden and prevalence trends (2000, 2011, 2024, and 2030 estimates)
Table 8. Global pen and injector drug delivery devices market revenue estimates and forecast, by product, 2021-2033 (USD Billion, Units)
Table 9. Major companies offering autoinjectors
Table 10. Key companies and their prefilled/smart pen product offerings
Table 11. Global pen and injector drug delivery devices market revenue estimates and forecast, by drug type, 2021-2033 (USD Billion, Units)
Table 12. Global injectors market, by drug type, 2021-2033 (USD Billion, Units)
Table 13. Global pen market, by drug type, 2021-2033 (USD Billion, Units)
Table 14. Key GLP-1 agonist pen products
Table 15. Global pen and injector drug delivery devices market revenue estimates and forecast, by therapeutic use, 2021-2033 (USD Billion, Units)
Table 16. Global ranking of countries by obesity prevalence (%)
Table 17. Global pen and injector drug delivery devices market revenue estimates and forecast, by end use, 2021-2033 (USD Billion, Units)
Table 18. Canada regulatory procedure for medical devices
Table 19. Cancer statistics and rankings for France, 2022
List of Figures
Figure 1. Pen and injector drug delivery devices market segmentation
Figure 2. Pen and injector drug delivery devices market segmentation
Figure 3. Market research process
Figure 4. Information procurement
Figure 5. Primary research pattern
Figure 6. Market research approaches
Figure 7. Value chain-based size & forecasting
Figure 8. Market formulation & validation
Figure 9. Pen and injector drug delivery devices market revenue
Figure 10. Volume price analysis
Figure 11. CDMO pen and injector drug delivery devices market revenue
Figure 12. Market snapshot (regional)
Figure 13. Segment snapshot (product)
Figure 14. Segment snapshot (drug type)
Figure 15. Segment snapshot (therapeutic use)
Figure 16. Segment snapshot (end use)
Figure 17. Market concentration
Figure 18. Pen and injector drug delivery devices market dynamics
Figure 19. Pen and injector drug delivery devices market: PORTER’s analysis
Figure 20. Pen and injector drug delivery devices market: PESTEL analysis
Figure 21. Estimated number of cancer cases in Europe, by Country, 2022 Vs. 2025 Vs 2030
Figure 22. Pen and injector drug delivery devices market, by product: Key takeaways
Figure 23. Pen and injector drug delivery devices market, by product: Market share, 2025 & 2033
Figure 24. Injectors market, 2021-2033 (USD Billion, Units)
Figure 25. Pens market, 2021-2033 (USD Billion, Units)
Figure 26. Pen and injector drug delivery devices market, by drug type: Key takeaways
Figure 27. Pen and injector drug delivery devices market, by drug type: Market share, 2025 & 2033
Figure 28. GLP-1 agonists market, 2021-2033 (USD Billion, Units)
Figure 29. Hormone therapies market, 2021-2033 (USD Billion, Units)
Figure 30. Biologics market, 2021-2033 (USD Billion, Units)
Figure 31. Others market, 2021-2033 (USD Billion, Units)
Figure 32. GLP-1 agonists market, 2021-2033 (USD Billion, Units)
Figure 33. Insulin market, 2021-2033 (USD Billion, Units)
Figure 34. Others market, 2021-2033 (USD Billion, Units)
Figure 35. Pen and injector drug delivery devices market, by therapeutic use: Key takeaways
Figure 36. Pen and injector drug delivery devices market, by therapeutic use: Market share, 2025 & 2033
Figure 37. Autoimmune disorders market, 2021-2033 (USD Billion, Units)
Figure 38. Hormonal disorders market, 2021-2033 (USD Billion, Units)
Figure 39. Oncology market, 2021-2033 (USD Billion, Units)
Figure 40. Obesity market, 2021-2033 (USD Billion, Units)
Figure 41. Diabetes mellitus market, 2021-2033 (USD Billion, Units)
Figure 42. Others market, 2021-2033 (USD Billion, Units)
Figure 43. Pen and injector drug delivery devices market, by end use: Key takeaways
Figure 44. Pen and injector drug delivery devices market, by end use: Market share, 2025 & 2033
Figure 45. Hospitals market, 2021-2033 (USD Billion, Units)
Figure 46. Homecare settings market, 2021-2033 (USD Billion, Units)
Figure 47. Others market, 2021-2033 (USD Billion, Units)
Figure 48. Pen and injector drug delivery devices market revenue, by region, 2025 & 2033 (USD Billion, Units)
Figure 49. Regional marketplace: Key takeaways
Figure 50. Regional marketplace: Key takeaways
Figure 51. North America pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 52. Estimated number of new cancer cases, by State -- 2025
Figure 53. Diagnosed diabetes - total, adults aged 18+ years, age-adjusted percentage (2023)
Figure 54. Reimbursement procurement process
Figure 55. U.S. pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 56. Diabetes mellitus (types combined), excluding gestational diabetes, age-standardized incidence rate, per 100,000, age 1 year old and older, Canada
Figure 57. Canada pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 58. Mexico pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 59. Europe pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 60. UK pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 61. Germany pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 62. France pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 63. Italy pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 64. Spain pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 65. Sweden pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 66. Norway pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 67. Denmark pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 68. Asia pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 69. China pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 70. Japan pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 71. India pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 72. Thailand pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 73. South Korea pen and injector drug delivery market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 74. Saudi Arabia pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 75. UAE pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 76. Kuwait pen and injector drug delivery devices market estimates and forecasts, 2021-2033 (USD Billion, Units)
Figure 77. Key company categorization
Figure 78. Company market share analysis, 2025
Figure 79. Strategy mapping

Companies Mentioned

The leading players profiled in this Pen and Injector Drug Delivery Devices market report include:
  • Novo Nordisk A/S
  • Sanofi
  • Eli Lilly and Company
  • AstraZeneca plc
  • Pfizer, Inc.
  • Merck KGaA
  • Teva Pharmaceuticals
  • Amgen, Inc.
  • Ferring Pharmaceuticals
  • AbbVie Inc.

Table Information